MCM
XENE icon

MAI Capital Management’s Xenon Pharmaceuticals XENE Stock Holding History

MAI Capital Management’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-392
Closed -$22.8K – 4745
2026
Q1 		$22.8K Buy
392
+131
+50% +$6.04K ﹤0.01% 2716
2025
Q4 		$11.7K Buy
+261
New +$11K ﹤0.01% 2787

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

MAI Capital Management's XENE Position: Q2 2026 in Review

MAI Capital Management sold out of Xenon Pharmaceuticals (XENE) in Q2 2026, closing a stake of 392 shares — an estimated $22.8K sold.

MAI Capital Management first reported a position in XENE in Q4 2025 and held it in 2 quarters. The position peaked at $22.8K in Q1 2026. 315 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

  • MAI Capital Management reported no remaining Xenon Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • MAI Capital Management sold 392 Xenon Pharmaceuticals shares in Q2 2026, an estimated $22.8K.
  • MAI Capital Management first reported a position in Xenon Pharmaceuticals in Q4 2025 and held it in 2 quarters.
  • MAI Capital Management's Xenon Pharmaceuticals position peaked at $22.8K in Q1 2026.
  • 315 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on MAI Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.